Price$42.07-1.20 (-2.78%)
01:45 PM06:45 PM
News · 26 weeks49+167%
2025-12-142026-06-07
Mix3690d
- Insider20(56%)
- Other8(22%)
- SEC Filings5(14%)
- Earnings2(6%)
- Leadership1(3%)
Latest news
25 items- PROmnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services BusinessSeasoned healthcare executive with deep expertise in specialty pharmacy operations named Senior Vice President and General Manager Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today announced that Dan Mandoli, a seasoned healthcare executive with more than 30 years of leadership across pharmacy operations and specialty pharmacy services, has joined the Company as Senior Vice President and General Manager, Specialty Pharmacy Services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608580918/en/Omnicell Welcomes Dan
- INSIDERDirector Bousa Edward Peter was granted 4,603 shares, increasing direct ownership by 26% to 22,589 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERDirector Scott Bruce E was granted 4,627 shares, increasing direct ownership by 20% to 27,600 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERDirector Seim Robin Gene was granted 4,845 shares, increasing direct ownership by 10% to 52,198 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERDirector Voynick Eileen J. was granted 4,785 shares, increasing direct ownership by 31% to 20,011 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERDirector Parrish Mark W was granted 4,845 shares, increasing direct ownership by 7% to 70,100 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERDirector Bauer Joanne B was granted 5,027 shares, increasing direct ownership by 11% to 49,922 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERDirector Garrett Mary was granted 5,027 shares, increasing direct ownership by 29% to 22,202 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERDirector Ghoshal Kaushik was granted 4,603 shares, increasing direct ownership by 32% to 19,123 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- PROmnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, announced that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Tuesday, June 9, 2026, at 3:20 PM EDT. Live and archived webcasts of the presentation will be available through the Omnicell website at: https://ir.omnicell.com/events-and-presentations/ About Omnicell Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying
- SECSEC Form SD filed by Omnicell Inc.SD - OMNICELL, INC. (0000926326) (Filer)
- SECOmnicell Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - OMNICELL, INC. (0000926326) (Filer)
- INSIDEREVP, Chief Operating Officer Njoku Nnamdi covered exercise/tax liability with 3,660 shares and sold $133,550 worth of shares (3,090 units at $43.22) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 154,785 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERVP, Chief Accounting Officer Nutt Brian H. covered exercise/tax liability with 226 shares, decreasing direct ownership by 0.98% to 22,860 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERCHAIRMAN, PRESIDENT AND CEO Lipps Randall A covered exercise/tax liability with 12,347 shares, decreasing direct ownership by 2% to 523,184 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDEREVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J covered exercise/tax liability with 4,041 shares and sold $217,180 worth of shares (5,025 units at $43.22) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 112,783 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Omnicell Inc.SCHEDULE 13G - OMNICELL, INC. (0000926326) (Subject)
- SECSEC Form 10-Q filed by Omnicell Inc.10-Q - OMNICELL, INC. (0000926326) (Filer)
- PROmnicell to Present at the BofA Securities 2026 Healthcare ConferenceOmnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, announced that it will present at the BofA Securities 2026 Healthcare Conference on Tuesday, May 12, 2026, at 8:40 a.m. PDT. Live and archived webcasts of the presentation will be available through the Omnicell website at: https://ir.omnicell.com/events-and-presentations/ About Omnicell Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying automation and
- PROmnicell Welcomes Hospital Pharmacy Leader Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical OfficerNewly established role strengthens understanding of healthcare clinician needs to help shape the Company's innovation priorities and portfolio decisions Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today announced that Rick Couldry has joined the Company as Senior Vice President, Chief Pharmacy and Clinical Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429498071/en/Omnicell Welcomes Rick Couldry to the Newly-Created Role of SVP, Chief Pharmacy and Clinical Officer In this newly created position, Couldry
- SECOmnicell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - OMNICELL, INC. (0000926326) (Filer)
- PROmnicell Announces First Quarter 2026 Financial ResultsOmnicell delivers strong first quarter 2026 financial results Raises full year 2026 non-GAAP EBITDA and non-GAAP EPS guidance Customer engagement underway for Omnicell Titan XT and OmniSphere Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today reported financial results for the first quarter ended March 31, 2026. First quarter results reflected strong execution across the business, supported by demand for Omnicell's connected device portfolio and solid performance across the Company's core points of care solutions. We believe that performance during the quarte
- PROmnicell to Release First Quarter 2026 Financial Results on April 28, 2026Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the first quarter 2026, before market open on Tuesday, April 28, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 9381205. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/event
- SECSEC Form DEF 14A filed by Omnicell Inc.DEF 14A - OMNICELL, INC. (0000926326) (Filer)
- PRAI-Driven Compliance Gamechanger in Pharma Manufacturing and Regulatory StandardsAUSTIN, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: As regulatory expectations intensify and manufacturing complexity grows, pharmaceutical companies are moving beyond traditional quality systems toward a new paradigm: embedding artificial intelligence (AI) directly into operations as a real-time compliance layer. Rather than relying on retrospective audits and manual oversight, AI-driven systems now continuously monitor, validate and optimize production processes to align with evolving Good Manufacturing Practice (GMP) standards. This structural shift is increasingly visible across the industry and aligns with companies such as Oncotelic Therapeutics Inc. (OTC
OMCL FAQ
7 questionsWhat does Omnicell Inc. do?
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve...Where does OMCL stock trade?
Omnicell Inc. (OMCL) is listed on NASDAQ.What sector and industry is OMCL in?
Omnicell Inc. operates in the Technology sector, Computer Manufacturing industry.When did Omnicell Inc. go public?
Omnicell Inc. (OMCL) completed its IPO in 2001.What are analysts saying about OMCL?
Omnicell Inc. has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Buy on 2026-02-04. Recent price targets range from $2800.00 to $3900.00.What companies are similar to OMCL?
Notable peers in the same industry include AAPL (Apple Inc.), IBM (International Business Machines Corporation), DELL (Dell Technologies Inc.), SMCI (Super Micro Computer Inc.), HPQ (HP Inc.). Compare OMCL side-by-side with any of them on Quantisnow.How can I track OMCL on Quantisnow?
Quantisnow aggregates Omnicell Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OMCL to receive live email and push alerts on every new disclosure.